Cite
HARVARD Citation
Balasubramanian, S. et al. (2022). Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. Cancer medicine. pp. 61-73. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Balasubramanian, S. et al. (2022). Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. Cancer medicine. pp. 61-73. [Online].